Of note, levels of LBP and the CCR9 ligand CCL25 were elevated in COVID‐19 patients, and it is tempting to hypothesize that LPS and CCL25 could contribute to gut mucosal impairment through promoting intestinal inflammation [37]. The gene discussed is CCR9; the disease is COVID-19.